ÂÜÀòÂÒÂ×

Cameron Black, Ph.D. has served as their Executive Vice President, Discovery since June 2016. Prior to joining us, Dr. Black co-founded Kanyr Pharma in 2013 and Kaneq Pharma in 2010 to develop drugs targeting cancer and metabolic disease, respectively. Prior to that, he spent nearly two decades at the Merck Frosst Center for Therapeutic Research, where he was responsible for the identification of seven drug candidates.

He led both the discovery and early clinical development of the cathepsin K inhibitor, odanacatib, a once-weekly treatment for osteoporosis. In 2010, he was made Site Scientific Operations Lead, responsible for the objectives and staffing of all discovery programs at Merck Frosst.

Dr. Black holds a B.Sc. in chemistry from the University of Saskatchewan and a Ph.D. in chemistry from Harvard University.